In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other top stocks to buy according to sustainable insight capital management. Sustainable ...

David Ricks, the CEO of Mounjaro and Zepbound maker Eli Lilly, explained why these medications are so expensive on the "In Good Company with Nicolai Tangen" podcast this week. 1. Time and money ...

Investors with a lot of money to spend have taken a bullish stance on Eli Lilly LLY. And retail traders should know. We noticed this today when the trades showed up on publicly available options ...

Eli Lilly’s (LLY) new weight loss pill is still in clinical trials and has not yet been approved by regulators. But that hasn’t stopped the pharmaceutical company from preparing for its launch.

(Reuters) - Eli Lilly is betting big on its experimental oral weight-loss drug even before reporting data from its late-stage trial by recording nearly $550 million in "pre-launch inventory" in ...

In ongoing trials of Eli Lilly’s (LLY) next-generation obesity drug, several trial participants are losing too much weight, STAT’s Elaine Chen reports. One participant lost 22% of her weight ...

At least $241 million in taxpayer funds was spent on transgender surgeries and animal experiments, prompting a congressional lawmaker to question the rationale behind the expenditures. Rep.

In its fourth quarter 2024 investor letter, Baron Health Care Fund emphasized stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company ...

Eli Lilly reported this morning. I want to talk about their revenue growth number, and I'm going to put it in some context of some younger growth stocks. These are the yearly revenue growth ...

BOSTON — Chris Kreider has never been one to think or talk in hypotheticals. Not even having one of the largest circuses of cameras and reporters huddled around his podium Tuesday, after he ...